Several studies suggest that pharmacological interventions targeting H2S may improve outcomes in IBD through mechanisms such as driving regulatory T cell differentiation, stabilizing hypoxia-inducible factor 1-alpha (HIF-1α), promoting biofilm formation, and reducing planktonic bacteria growth [14–16]. The gene discussed is HIF1A; the disease is inflammatory bowel disease.